LLY

1,009.78

+2.29%↑

JNJ

230.21

+1.07%↑

ABBV

213.46

+1.18%↑

UNH

393.26

+1.95%↑

AZN

185.37

+0.94%↑

LLY

1,009.78

+2.29%↑

JNJ

230.21

+1.07%↑

ABBV

213.46

+1.18%↑

UNH

393.26

+1.95%↑

AZN

185.37

+0.94%↑

LLY

1,009.78

+2.29%↑

JNJ

230.21

+1.07%↑

ABBV

213.46

+1.18%↑

UNH

393.26

+1.95%↑

AZN

185.37

+0.94%↑

LLY

1,009.78

+2.29%↑

JNJ

230.21

+1.07%↑

ABBV

213.46

+1.18%↑

UNH

393.26

+1.95%↑

AZN

185.37

+0.94%↑

LLY

1,009.78

+2.29%↑

JNJ

230.21

+1.07%↑

ABBV

213.46

+1.18%↑

UNH

393.26

+1.95%↑

AZN

185.37

+0.94%↑

Home・Lista de Ações・Heron Therapeutics Inc

Heron Therapeutics Inc

Abrir

SetorSaúde

0.85 -1.16

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

0.84

Máximo

0.88

Indicadores-chave
By Trading Economics
Rendimento	-5.2M -8.1M
Vendas	-5.9M 35M
EPS	-0.04
Margem de lucro	-23.367
Funcionários	128
EBITDA	-4M -4.8M

Recomendações
By TipRanks
Recomendações	Comprar
Previsão para 12 meses	+311.76% upside

Dividendos
By Dow Jones
Próximos Ganhos	7 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-49M 181M
Abertura anterior	2.01
Fecho anterior	0.85

Sentimento de Notícias

By Acuity

67%

33%

298 / 345 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Bearish Evidence

2.0001 / 2.42 Suporte e Resistência

Heron Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

18 de mai. de 2026, 23:10 UTC

Ações em Alta

Stocks to Watch: Agilysys, XP

18 de mai. de 2026, 18:44 UTC

Grandes Movimentos do Mercado

Claritev Shares Recover After Comments About DOJ

18 de mai. de 2026, 23:55 UTC

Ganhos

Review & Preview: Earnings' Last Gasp -- Barrons.com

18 de mai. de 2026, 23:47 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

18 de mai. de 2026, 23:47 UTC

Conversa de Mercado

Nikkei May Rise on Hopes for U.S.-Iran Deal -- Market Talk

18 de mai. de 2026, 23:37 UTC

Conversa de Mercado

Gold Rises Amid Hopes for U.S.-Iran Peace Deal -- Market Talk

18 de mai. de 2026, 22:31 UTC

Aquisições, Fusões, Aquisições de Empresas

Lens Technology Ju Teng International Shares to Resume Trading on Hong Kong Exchange on May 19

18 de mai. de 2026, 22:30 UTC

Aquisições, Fusões, Aquisições de Empresas

Lens Technology: Acquisition of Remaining Ju Teng International Shares to Cost HK$1.91B

18 de mai. de 2026, 22:30 UTC

Aquisições, Fusões, Aquisições de Empresas

Lens Technology to Make Offer for Remainder Shares of Ju Teng International Only After Completion of Stake Purchase

18 de mai. de 2026, 22:25 UTC

Aquisições, Fusões, Aquisições de Empresas

Lens Technology to Acquire 333.71M Ju Teng International Shares for HK$2.20 Each

18 de mai. de 2026, 22:24 UTC

Aquisições, Fusões, Aquisições de Empresas

Lens Technology to Acquire 27.81% Stake in Ju Teng International for HK$734.17M

18 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

18 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Aquisições, Fusões, Aquisições de Empresas

Financial Services Roundup: Market Talk

18 de mai. de 2026, 20:25 UTC

Ganhos

Correct: XP 1Q Total Client Assets BRL1.53T

18 de mai. de 2026, 20:23 UTC

Ganhos

XP 1Q Total Client Assets BRL1.53B

18 de mai. de 2026, 20:19 UTC

Ganhos

XP 1Q Adj EPS BRL2.49 >XP

18 de mai. de 2026, 20:19 UTC

Ganhos

XP 1Q Rev BRL4.73B >XP

18 de mai. de 2026, 19:10 UTC

Conversa de Mercado

Oil Presses Higher With No Hormuz Reopening in Sight -- Market Talk

18 de mai. de 2026, 19:00 UTC

Ganhos

5 Stocks with 5% Yields and Market-Beating Returns -- Barrons.com

18 de mai. de 2026, 18:52 UTC

Conversa de Mercado

U.S. Natural Gas Futures Gain As Weather Heats Up -- Market Talk

18 de mai. de 2026, 18:17 UTC

Conversa de Mercado

Aquisições, Fusões, Aquisições de Empresas

NextEra's Dominion Acquisition Unlikely to Spur Wider Utility Consolidation -- Market Talk

18 de mai. de 2026, 17:22 UTC

Conversa de Mercado

Tokenized Assets Expected to be Over $1T By 2030 -- Market Talk

18 de mai. de 2026, 16:57 UTC

Aquisições, Fusões, Aquisições de Empresas

The Long Regulatory Road Ahead for the NextEra-Dominion Deal -- Barrons.com

18 de mai. de 2026, 16:57 UTC

Conversa de Mercado

Global Energy Roundup: Market Talk

18 de mai. de 2026, 16:57 UTC

Conversa de Mercado

Commodities Higher as Traders Want Physical Assets -- Market Talk

18 de mai. de 2026, 16:54 UTC

Aquisições, Fusões, Aquisições de Empresas

Vinci Doesn't Set Out Financial Details of Deal

18 de mai. de 2026, 16:50 UTC

Aquisições, Fusões, Aquisições de Empresas

Vinci: Acquisition of New Brunswick-Based Group Stregthens Presence in Eastern Canada

18 de mai. de 2026, 16:49 UTC

Aquisições, Fusões, Aquisições de Empresas

Vinci: Modern Group is Roadwork, Civil Engineering Specialist

18 de mai. de 2026, 16:49 UTC

Aquisições, Fusões, Aquisições de Empresas

Vinci: Modern Group Made Revenue of Around 50 Mln Euros Last Year

18 de mai. de 2026, 16:48 UTC

Aquisições, Fusões, Aquisições de Empresas

Vinci Buys Canada's Modern Group of Companies

Comparação entre Pares

Variação de preço

Heron Therapeutics Inc Previsão

Preço-alvo

By TipRanks

311.76% parte superior

Previsão para 12 meses

Média 3.5 USD 311.76%

Máximo 4 USD

Mínimo 3 USD

Com base em 2 analistas de Wall Street que oferecem metas de preço de 12 meses para Heron Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

2 ratings

Comprar

Manter

Vender

Com base em 2 analistas que deram avaliações de ações para Heron Therapeutics Inc - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

2.0001 / 2.42Suporte e Resistência

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Sentimento

By Acuity

298 / 345 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Heron Therapeutics Inc

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.